Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Notes that its partner in autism spectrum disorder and other neurodevelopmental disorders Stalicla SA has announced that it has raised USD17.4 million, inclusive of a credit facility. This is to to support programmes on STP1, Stalicla's first asset in ASD, and a further asset in substance use disorders together with a biosampling and patient identification study in ASD. Evgen says it continues to work with Stalicla on delivery of a milestone payment for SFX-01 (Stalicla's STP2). Evgen says both parties are engaged in analysis and interpretation of Evgen's recent Phase 1b healthy volunteer PK/PD study and the implications for a future phase 2 trial in ASD. Evgen says it will provide updates on the status of the programme in "due course" and has not anticipated any milestone payments from Stalicla in its financial forecasting.
Evgen Chief Executive Officer Huw Jones comments: "We extend our congratulations to Stalicla on this round of financing and look forward to continuing discussions on SFX-01 in ASD. In the meantime we continue to advance our internal programme in glioblastoma with the Erasmus medical centre in Rotterdam and our pre-clinical programmes in rhabdomyosarcoma, glioblastoma, bowel cancer and breast cancer with our leading academic collaborators."
Current stock price: 1.35 pence, down 10%
12-month change: down 72%
By Greg Rosenvinge, Alliance News senior reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.